Company
Enliven Therapeutics Inc (NASDAQ:ELVN)’s 12-Month Price Target Is Now Set At 39.
In last trading session, Enliven Therapeutics Inc (NASDAQ:ELVN) saw 0.66 million shares changing hands with its beta currently measuring 0.79. Company’s recent per share price